
    
      Subjects received sipuleucel-T at 2-week intervals, for a total of 3 infusions. The study
      evaluated the safety and magnitude of the immune responses to treatment with sipuleucel-T.
      All subjects were followed for 30 days following the last infusion of sipuleucel-T. Following
      the Study Completion Visit, survival, treatment-related serious adverse event (SAE)s and
      cerebrovascular event (CVE)s were collected via Long Term Follow-up Telephone Assessment
      occurring Q6 months.
    
  